<DOC>
	<DOCNO>NCT00358540</DOCNO>
	<brief_summary>The study evaluate safety tolerability , optimal biologic dose , pharmacokinetics eltrombopag patient advance sarcoma low platelet count receive ADRIAMYCIN ifosfamide ( AI ) chemotherapy .</brief_summary>
	<brief_title>Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Inclusion criterion : Adult subject , 18 year old Adequate liver kidney function Prior history ≥grade 2 thrombocytopenia ( platelet nadir ≤ 75,000/microliters ) Ability ingest retain oral medication Practice acceptable birth control Ability understand follow study requirement Life expectancy least 3 month Exclusion criterion : History platelet disorder , dysfunction , bleed disorder Anticoagulant use within 2 week prior study start Females lactate expect History thromboembolic event drug induce thrombocytopenia History central nervous system , brain and/or leptomeningeal metastasis Prior surgery within 2 week radiotherapy within 4 week study start Preexisting cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>sarcoma</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>eltrombopag</keyword>
	<keyword>thrombopoiesis</keyword>
</DOC>